Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 symbols : Rdhl save search
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 6.63%
H: 12.99%
C: 6.78%
rhb-107 covid-19 funding study phase 2
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
Published: 2023-07-31 (Crawled : 16:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 1.56%
H: 4.62%
C: -1.54%
rhb-107 covid-19 fda cleared trial platform
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 15.68%
H: 26.31%
C: 9.06%
rhb-107 covid-19 positive results publication study phase 2
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Published: 2022-10-19 (Crawled : 12:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 92.89%
H: 7.26%
C: -24.02%
covid-19 treatment patent granted
RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences
Published: 2022-07-12 (Crawled : 13:20) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 0.0%
H: 0.94%
C: -3.77%
covid-19 publication
RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: -3.42%
H: 17.26%
C: -7.96%
covid-19 drug opaganib in vitro
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
Published: 2022-03-01 (Crawled : 14:30) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 0.46%
H: 0.45%
C: -10.45%
rhb-107 covid-19 phase 2 covid positive
RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19
Published: 2022-02-07 (Crawled : 22:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: -0.79%
H: 10.76%
C: -4.78%
covid-19 biopharma ces opaganib covid
RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients
Published: 2022-01-13 (Crawled : 18:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 0.82%
H: 6.1%
C: -2.44%
covid-19 phase 2 biopharma clearance phase 2/3 opaganib covid
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
Published: 2021-08-26 (Crawled : 11:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 4.46%
H: 3.33%
C: -2.8%
covid biopharma opaganib covid-19
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
Published: 2021-07-19 (Crawled : 12:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 2.37%
H: 7.45%
C: 3.64%
covid phase 2 biopharma phase 2/3 opaganib covid-19
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 2.3%
H: 0.0%
C: -1.4%
covid biopharma opaganib preclinical covid-19 pre-clinical
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
Published: 2021-06-21 (Crawled : 12:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 0.43%
H: 1.57%
C: -1.14%
covid presentation phase 2 biopharma positive opaganib covid-19
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 0.57%
H: 4.78%
C: 3.38%
covid phase 2 biopharma phase 2/3 opaganib enroll covid-19
RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19
Published: 2021-05-26 (Crawled : 15:15) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 4.63%
H: 1.43%
C: 0.71%
covid biopharma opaganib patent application covid-19
RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland
Published: 2021-03-22 (Crawled : 12:00) - biospace.com/
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 2.13%
H: 1.82%
C: 0.0%
covid treatment biopharma switzerland opaganib covid-19
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.